Compare Bristol-Myers Squibb Co (BMY) vs Realty Income Corp (O) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

Realty Income (O) trades at $64.17, up 1.36% with a bullish technical outlook. The stock shows strong fundamentals with $5.75B revenue and 19.05% net income margin, though recent quarters have missed EPS estimates. Recent credit facility expansion to $5.5B supports growth initiatives, particularly in European markets. Dividend payments remain consistent at $0.27 quarterly, providing stable income for investors.

Outlook remains positive with analyst consensus target of $67.86 representing 5.8% upside. Risks include elevated P/E ratio of 51.89 and three consecutive quarterly earnings misses. The company's expansion strategy and strong cash flow generation support long-term growth potential, though valuation concerns warrant monitoring of future earnings performance.